logo

Alexion Pharmaceuticals Inc. (ALXN)



Trade ALXN now with
  Date
  Headline
11/2/2018 11:07:42 AM Alexion Closes Acquisition Of Syntimmune
10/24/2018 6:38:47 AM Alexion Q3 GAAP EPS $1.47; Non-GAAP EPS $2.02
10/24/2018 6:32:06 AM Alexion And Dicerna Announce Collaboration To Develop RNAi Therapies For Complement-Mediated Diseases
9/26/2018 6:31:43 AM Alexion To Acquire Syntimmune For A Total Value Of Up To $1.2 Bln
8/20/2018 6:34:19 AM Alexion Pharma: FDA Accepts Priority Review Of ALXN1210
7/26/2018 7:58:49 AM Alexion Pharmaceuticals Inc. (ALXN) Has Raised Its FY18 EPS Estimate To 7.00 - 7.15 From 6.75 - 6.90
7/26/2018 7:57:53 AM Alexion Pharmaceuticals Inc. (ALXN) Has Raised Its FY18 Revenue Estimate To $3,980 to $4,010 Mln From $3,925 to $3,985 Mln
7/26/2018 7:56:37 AM Alexion Pharmaceuticals Inc. (ALXN) Has Raised Its FY18 EPS Estimate To $7.00 to $7.15 From $6.75 to $6.90
7/26/2018 6:31:18 AM Alexion Q2 GAAP Loss Per Share Of $2.05; Non-GAAP EPS Of $2.07
6/28/2018 6:35:53 AM Alexion Submits Application For Approval Of ALXN1210 As A Treatment For Patients With PNH In The European Union